Ran You
Jiangsu Key Laboratory Of Pediatrics
Nanjing, China
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Enhanced WWP2 Exacerbates Podocyte Injury in Lupus Nephritis through Monoubiquitylating H2A at K119.
Enhanced WWP2 Exacerbates Podocyte Injury in Lupus Nephritis through Monoubiquitylating H2A at K119.
Journal: International journal of biological sciences
Published: January 14, 2026
Design and Evolution of an Artificial Aldolase with an Abiological Catalytic Cofactor in Apo-Myoglobin.
Journal: Organic letters
Published: September 05, 2025
Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second-Line Treatment Failure.
Journal: Cancer medicine
Published: August 28, 2025
Targeting renal tubular WWP2 to restore mitochondrial OXPHOS integrity retards the AKI-to-CKD transition.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 04, 2025
Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series.
Journal: Discover oncology
Published: May 25, 2025
Biosynthesis of functional carbohydrates from glycolytic node precursors glucose-6-phosphate and fructose-6-phosphate: Advances and prospects.
Journal: Biotechnology advances
Published: April 14, 2025
Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma.
Journal: Discover oncology
Published: February 13, 2025
Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy After Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Journal: Drugs - real world outcomes
Published: December 24, 2024
Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma.
Journal: Discover oncology
Published: December 23, 2024
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study.
Journal: Investigational new drugs
Published: November 11, 2024
A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: July 13, 2024
Last Updated: 09/26/2026